Industries > Pharma > Chinese Pharmaceutical Market Forecast 2017-2027

Chinese Pharmaceutical Market Forecast 2017-2027

Cardiovascular Diseases, Oncology, Respiratory Diseases, Infectious Diseases, Diabetes, CNS, Autoimmune Diseases, Hypertension, Dyslipidaemia, COPD, Asthma, Antidepressants, Small Molecules, Branded Drugs, Traditional Chinese Medicine, Biologics, Vaccines, Biosimilars, Generic Prescription Drugs, Over-the-Counter Drugs, Patented Prescription Drugs, Hospitals, Retail Pharmacies, Grassroots Clinics

PUBLISHED: 18 September 2017
PAGES: 253
PRODUCT CODE: PHA0238

Clear
WOOCS 2.2.1

The Chinese Pharmaceutical market is expected to grow at a CAGR of 12.3% in the second half of the forecast period. The Chinese Pharmaceutical market reached $145.4bn in 2016, dominated by the Cardiovascular therapy area which held 13.6% share of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 253-page report you will receive 68 tables and 90 figures– all unavailable elsewhere.

The 253-page report provides clear detailed insight into the Chinese Pharmaceutical market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Chinese Pharmaceutical Market Forecast 2017-2027

Report Scope

Chinese Pharmaceutical market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by therapy area:
– Cardiovascular: including specific revenue forecasts for Hypertension and Dyslipidaemia
– Anticancer
– Infectious Diseases
– Diabetes
– Respiratory:
including specific revenue forecasts for Asthma and COPD
– Central Nervous System:
including specific revenue forecasts for Antidepressants
– Autoimmune
– Others

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket. Moreover, this report discusses the drivers and restraints of each submarket.

• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by leading product class:
– Small Molecules: further broken down into Generics Drugs and Branded Drugs
– Traditional Chinese Medicine
– Biologics: further broken down into Biologics (branded), Vaccines and Biosimilars

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket. Moreover, this report discusses the drivers and restraints of each submarket.

• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by leading type of drug:
– Generic Prescription Drugs
– Over-the-Counter (OTC) Drugs
– Patented Prescription Drugs

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket.

• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by sales channel:
– Hospitals
– Retail Pharmacies
– Grassroots Clinics

This report lists and discusses the domestic pharmaceutical companies that dominate each submarket.

• This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT) that influence the Chinese Pharmaceutical Market. It also analyses social, technological, economic and political factors (STEP) that influence the Chinese Pharmaceutical Market

• Our study ranks and provides 2016 revenues as well as market share of the top 50 domestic Chinese Pharmaceutical companies and top 10 Multinational Pharmaceutical Companies that are the major players in the Chinese Pharmaceutical Market

• Our study lists and discusses the leading domestic and multinational Contract Research Organizations (CRO) that dominate the Chinese Pharmaceutical Market.

Visiongain’s study is intended for anyone requiring commercial analyses for the Chinese Pharmaceutical market. You find data, trends and predictions.

Buy our report today Chinese Pharmaceutical Market Forecast 2017-2027: Cardiovascular Diseases, Oncology, Respiratory Diseases, Infectious Diseases, Diabetes, CNS, Autoimmune Diseases, Hypertension, Dyslipidaemia, COPD, Asthma, Antidepressants, Small Molecules, Branded Drugs, Traditional Chinese Medicine, Biologics, Vaccines, Biosimilars, Generic Prescription Drugs, Over-the-Counter (OTC) Drugs, Patented Prescription Drugs, Hospitals, Retail Pharmacies, Grassroots Clinics, Domestic Pharmaceutical Companies, Multinational Pharmaceutical Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Chinese Pharmaceutical Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Chinese Pharmaceutical Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories